47 reports

  • Schizophrenia and Psychotic Disorders
  • 2.2 Psychotic Disorder: An Overview

Eating Disorders ##. ##. ## PSYCHOTIC DISORDER: DEFINITION ##. ## Psychotic Disorder: An Overview Psychotic disorders are a group of serious illnesses that affect the mind.

  • Psychotic Disorder
  • Alkermes plc
  • Eli Lilly & Co.
  • Janssen Biotech, Inc.
  • Johnson & Johnson
  • CPL-50003602 - DRUG PROFILE
  • Phase I - Trial Details

RESEARCHERS IDENTIFIED ##-[##-FLUORO-##-(##H-PYRAZOL-##-YL)PHENYL]-##-METHOXY-##-(##-PHENYL-##H-PYRAZOL-##YL)PYRIDAZIN-##(##H)-ONE (##H).

  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • World
  • Product Initiative
  • CPL-50003602 - DRUG PROFILE
  • BALIPODECT - DRUG PROFILE

Researchers identified ##-[##-fluoro-##-(##H-pyrazol-##-yl)phenyl]-##-methoxy-##-(##-phenyl-##H-pyrazol-##yl)pyridazin-##(##H)-one (##h).

  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • World
  • Product Initiative
  • PLACEBO ON PANSS TOTAL AND SUBSCALE SCORES (POSITIVE AND NEGATIVE) AND CGI-SEVERITY SCORE.

LATUDA IS INDICATED FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA, AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION), AS ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE TREATMENT OF PAT

  • Pharmaceutical
  • Psychotic Disorder
  • United States
  • World
  • Product Initiative
  • CPL-50003602 - Drug Profile
  • Phase II - Trial Details

Researchers identified ##-[##-fluoro-##-(##H-pyrazol-##-yl)phenyl]-##-methoxy-##-(##-phenyl-##H-pyrazol-##yl)pyridazin-##(##H)-one (##h).

  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • World
  • Product Initiative
  • DRUG TO AGONIZE CHRM4 FOR PSYCHOSIS - DRUG PROFILE

The presentation is entitled as Sigma-## Receptor Agonists as Potential Treatment Options for Autism Spectrum Disorders: Pre-clinical Studies with ANAVEX ##-## in a Fragile X Model".

  • Psychotic Disorder
  • United States
  • World
  • Product Initiative
  • Anavex Life Sciences Corp.
  • R&D Progress Research and Development Brief
  • SERX-480 - DRUG PROFILE

psychotic disorders, psychosis, obsessive-compulsive disorder, binge eating disorders, sedation and attention deficit hyperactivity disorder (ADHD).

  • Pharmaceutical
  • Psychotic Disorder
  • United States
  • Product Initiative
  • Reviva Pharmaceuticals Inc.

The number of people suffering from psychotic disorders is also increasing in India.

  • Neurological Monitoring
  • Psychotic Disorder
  • North America
  • United States
  • Market Size
  • R&D Progress Research and Development Brief

psychotic disorders, psychosis, obsessive-compulsive disorder, binge eating disorders, sedation and attention deficit hyperactivity disorder (ADHD).

  • Pharmaceutical
  • Psychotic Disorder
  • United States
  • Product Initiative
  • Reviva Pharmaceuticals Inc.
  • DRUG TO AGONIZE CHRM4 FOR PSYCHOSIS - DRUG PROFILE

As of May 2018, it was in Phase I stage for bipolar disorder.

  • Psychotic Disorder
  • United States
  • World
  • Product Initiative
  • Anavex Life Sciences Corp.
  • 8.5.2 SCHIZOPHRENIA MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
  • 8.5 SCHIZOPHRENIA 8.5.1 OVERVIEW

According to the National Institutes of Health (NIH), the prevalence of schizophrenia and related psychotic disorders in the U. S. range between ##. ##% and ##. ##%.

  • Psychotic Disorder
  • Forecast
  • Market Size
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • 4. DRUG/MOLECULE REFERS TO PRIMARY INTERVENTION ONLY.

USA) Central Nervous System Psychosis, Schizoaffective Disorder, Schizophrenia, Schizophreniform Disorder (C Reactive Protein (Pentraxin ## or CRP), Carbohydrate Antigen ##-## (CA##-##)) Completed Phase II/ III Interventional Cellavie; ethyl-eicosapentaenoic acid Oslo Un

  • Drug Development
  • Pharmaceutical
  • Psychotic Disorder
  • World
  • Product Initiative
  • CPL-50003602 - Drug Profile
  • PHASE II - TRIAL DETAILS

Researchers identified ##-[##-fluoro-##-(##H-pyrazol-##-yl)phenyl]-##-methoxy-##-(##-phenyl-##H-pyrazol-##yl)pyridazin-##(##H)-one (##h).

  • Hospital
  • Pharmaceutical
  • Psychotic Disorder
  • World
  • Product Initiative
  • Clinical Trial profile. 525 Trial Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

SCHIZOAFFECTIVE DISORDER THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2020* SCHIZOAFFECTIVE DISORDER THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2020* SCHIZOAFFECTIVE DISORDER THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE,

  • Clinical Trial
  • Neurology
  • Psychotic Disorder
  • United States
  • World
  • SMALL MOLECULE TO INHIBIT VMAT-2 FOR BIPOLAR DISORDER, MOVEMENT DISORDERS AND SCHIZOPHRENIA - DRUG PROFILE
  • GWP-42003 - DRUG PROFILE

The most common were worsening of schizophrenia (##. ##%) and psychotic disorder (##. ##%).

  • Mental Health
  • Psychotic Disorder
  • United States
  • Product Initiative
  • Omeros Corporation

Its products are indicated for the treatment of diseases such as Alzheimer' s disease, depression, Parkinson' s disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, epilepsy and Huntington' s disease, among others.

  • Psychotic Disorder
  • Therapy
  • United States
  • Company Financials
  • Acorda Therapeutics, Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

CLINICAL TRIALS BY PHASE IN E## COUNTRIES SCHIZOPHRENIFORM DISORDER THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2020* SCHIZOPHRENIFORM DISORDER THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2020* SCHIZOPHRENIFORM DISORDER THERAPEUTICS, E## COUNTRIES, CLINIC

  • Clinical Trial
  • Psychotic Disorder
  • Therapy
  • World
  • Product Initiative
  • lurasidone hydrochloride - Drug Profile

Adverse events associated with SEROQUEL XR (greater than or equal to ##%) included schizophrenia, headache, insomnia, psychotic disorder, increased weight and agitation.

  • Antipsychotic
  • Depression
  • Psychotic Disorder
  • United States
  • Product Initiative

The Cerezyme patient discontinued due to psychotic disorder, deemed unrelated to treatment.

  • Psychotic Disorder
  • Therapy
  • United States
  • Product Initiative
  • Genzyme Corporation
  • Target
  • 5. All the trials included are unique trials.

SCHIZOAFFECTIVE DISORDER THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* SCHIZOAFFECTIVE DISORDER THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* Country Name Phase IV Phase III/ IV Phase III Phase II/ III Phase II Phase I/ II Phase I Phase ## Tot

  • Clinical Trial
  • Neurology
  • Psychotic Disorder
  • World
  • Product Initiative
  • AUG 25, 2016: THE LARGEST AND LONGEST STUDY OF PATIENTS WITH SCHIZOPHRENIA INTERACTING WITH DIGITAL THERAPEUTICS RESULTS RELEASED

The study evaluated ## participants between ##-## years of age, who had been diagnosed with a psychotic disorder and were discharged from a psychiatric hospitalization within ## days.

  • Clinical Trial
  • Psychotic Disorder
  • Therapy
  • United States
  • Product Initiative
  • Clinical Trial profile. 274 Trial Title
  • Clinical Trial profile. 171 Trial Title

## ## ## ## ## ## ## ## China ## ## ## ## ## ## ## ## Russia ## ## ## ## ## ## ## ## Brazil ## ## ## ## ## ## ## ## Mexico ## ## ## ## ## ## ## ## Turkey Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are ta

  • Antipsychotic
  • Clinical Trial
  • Psychotic Disorder
  • Therapy
  • World
  • DRUG TO AGONIZE CHRM4 FOR DRUG-INDUCED DYSKINESIA - DRUG PROFILE

GENETIC VARIATION IN VMAT## IS LINKED TO ALTERATIONS IN COGNITIVE FUNCTIONING UNDERLYING PSYCHOTIC DISORDER, THROUGH ALTERED TRANSPORT OF MONOAMINES INTO SYNAPTIC VESICLES.

  • Mental Health
  • Psychotic Disorder
  • Australia
  • United States
  • Product Initiative

Patients are randomized ##:## to placebo or SYN## dosed once daily over a ## week treatment period.

  • Psychotic Disorder
  • Therapy
  • United States
  • Company
  • Biotie Therapies Corp.
  • SERX-480 - DRUG PROFILE

RP## is also under development for the treatment of brain disorders such as from major depressive disorder (MDD), manic-depressive bipolar disorder, psychosis in Parkinson' s and Alzheimer' s diseases, Tourette' s syndrome, autism and attention defic

  • Pharmaceutical
  • Psychotic Disorder
  • United States
  • Product Initiative
  • Reviva Pharmaceuticals Inc.
  • CPL-50003602 - Drug Profile

Researchers identified ##-[##-fluoro-##-(##H-pyrazol-##-yl)phenyl]-##-methoxy-##-(##-phenyl-##H-pyrazol-##yl)pyridazin-##(##H)-one (##h).

  • Hospital
  • Pharmaceutical
  • Psychotic Disorder
  • World
  • Product Initiative
  • R&D Progress Research and Development Brief

The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ## and ## respectively.

  • Psychotic Disorder
  • United States
  • World
  • Product Initiative
  • Reviva Pharmaceuticals Inc.
  • Apr 25, 2018: How the brain is folded provides researchers with an accurate marker to predict psychosis in high-risk patients
  • Mar 05, 2018: Early psychosis programs significantly reduce patient mortality, study finds

The researchers point out that approximately ## in ## young people experience psychosis-risk symptoms, but only one per cent will develop long-standing psychotic disorders such as schizophrenia.

  • Healthcare
  • Psychotic Disorder
  • Canada
  • Company
  • Deals & Alliance
  • lurasidone hydrochloride - Drug Profile

Adverse events associated with SEROQUEL XR (greater than or equal to ##%) included schizophrenia, headache, insomnia, psychotic disorder, increased weight and agitation.

  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • United States
  • Product Initiative

The disorder can be BIPOLAR DISORDER divided into two types: bipolar disorder type I, characterized by at least one episode of mania with or without a depressive episode, whereas the bipolar disorder type II is characterized by at least one hypom

  • Psychotic Disorder
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • GlaxoSmithKline plc
  • Johnson & Johnson